Eric Jonasch MDProfessor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine; Director, VHL Clinical Center, The University of Texas MD Anderson Cancer Center, Houston, Texas
Eric Jonasch is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, at the MD Anderson Cancer Center of The University of Texas in Houston, where he is also Co-Chair of the Renal Cancer Program. Since 2003, Dr. Jonasch has been the Director of the Von Hippel Lindau (VHL) Clinical Center in Houston. He performs clinical, translational, and basic research in VHL disease and kidney cancer.
After receiving his MDCM degree from McGill University Faculty of Medicine, Dr. Jonasch underwent clinical residency in internal medicine at the Royal Victoria Hospital in Montreal. Subsequently, he completed a research fellowship in Hematology/Oncology at the New England Medical Center in Boston, as well as a clinical fellowship. He was then awarded a research fellowship at the Beth Israel Deaconess Medical Center in Boston.
Dr. Jonasch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the American Urological Association, and the National Comprehensive Cancer Network. He serves as a board member and Director of the Clinical Advisory and Research Councils of the VHL Alliance and serves on the Medical Advisory Board of the Kidney Cancer Association; he is a member of the NCI PDQ Cancer Genetics Editorial Board.
Additionally, Dr. Jonasch has published widely in many peer-reviewed journals and has contributed to and published various books.
Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center
Director, VHL Clinical Center, MD Anderson Cancer Center
Co-Chair, Renal Cancer Program, MD Anderson Cancer Center
Board Member and Director of Clinical Advisory and Research Councils, VHL Alliance, Boston, Massachusetts
Member, Kidney Cancer Association Medical Advisory Board, Chicago, Illinois
Member, NCI PDQ Cancer Genetics Editorial Board
Vice Chair, Kidney/Testicular Cancers Panel, National Comprehensive Cancer Network
McGill University Faculty of Medicine, MDCM
Postdoctoral research fellow, Beth Israel Deaconess Medical Center, Boston
Postdoctoral clinical fellow, New England Medical Center, Boston
Postdoctoral research fellow, Hematology/Oncology, New England Medical Center, Boston
Board Certifications:Medical Oncology, American Board of Internal Medicine
Oncology, Royal College of Physicians & Surgeons of Canada
Medicine, Royal College of Physicians & Surgeons of Canada
Hematology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
Eric Jonasch MD serves as a consultant to Bristol-Myers Squibb Company, Pfizer Inc. Glaxo SmithKline plc, Novartis AG, Exelixis Inc, Cerulean Inc. and Genentech Inc.; and has received research/grant support from Exelixis Inc, Pfizer Inc., and Novartis AG.
Recent Contributions to PracticeUpdate:
- PBRM1 as a Biomarker for Renal Cell Carcinoma
- Frontline Management of Renal Cell Carcinoma
- Hemangioblastoma and VHL Disease
- ASCO: Updated Results of a Clinical Trial Evaluating Pembrolizumab Plus Axitinib for Frontline Treatment of Advanced RCC
- ASCO: Savolitinib for Patients With MET-Driven Papillary Renal Cell Carcinoma
- ASCO: A Novel Therapy for VHL Disease-Associated Renal Cell Carcinoma
- ASCO 2020: Abstract Recommendations From Dr. Eric Jonasch for Renal Cell Carcinoma
- Spinal Paraganglioma as an Unusual Finding in VHL Disease
- Contextualizing New Data on Checkpoint Inhibitors for Non–Clear Cell RCC
- AACR: Early Data on Targeting PBRM1 Mutations